Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:LNTH NASDAQ:PTCT NASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$4.77-1.8%$5.13$4.57▼$8.69$1.81B0.422.77 million shs1.93 million shsLNTHLantheus$102.37-2.9%$101.46$47.25▼$111.86$6.86B-0.06927,765 shs782,917 shsPTCTPTC Therapeutics$78.06-4.0%$76.15$43.17▼$90.87$6.75B0.532.53 million shs1.62 million shsSRRKScholar Rock$53.78-1.7%$49.71$27.07▼$58.49$6.55B0.671.76 million shs1.09 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-1.85%-3.05%-5.74%-17.20%-24.78%LNTHLantheus-2.87%-1.01%-2.06%+21.96%+23.25%PTCTPTC Therapeutics-4.02%-12.49%+3.89%+6.10%+57.82%SRRKScholar Rock-1.68%-4.92%+21.73%+9.04%+39.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$4.77-1.8%$5.13$4.57▼$8.69$1.81B0.422.77 million shs1.93 million shsLNTHLantheus$102.37-2.9%$101.46$47.25▼$111.86$6.86B-0.06927,765 shs782,917 shsPTCTPTC Therapeutics$78.06-4.0%$76.15$43.17▼$90.87$6.75B0.532.53 million shs1.62 million shsSRRKScholar Rock$53.78-1.7%$49.71$27.07▼$58.49$6.55B0.671.76 million shs1.09 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-1.85%-3.05%-5.74%-17.20%-24.78%LNTHLantheus-2.87%-1.01%-2.06%+21.96%+23.25%PTCTPTC Therapeutics-4.02%-12.49%+3.89%+6.10%+57.82%SRRKScholar Rock-1.68%-4.92%+21.73%+9.04%+39.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.80Reduce$8.0067.89% UpsideLNTHLantheus 2.73Moderate Buy$108.295.78% UpsidePTCTPTC Therapeutics 2.80Moderate Buy$91.5717.31% UpsideSRRKScholar Rock 3.12Buy$56.004.13% UpsideCurrent Analyst Ratings BreakdownLatest BHC, PTCT, LNTH, and SRRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026LNTHLantheus B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$97.00 ➝ $129.007/7/2026PTCTPTC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$82.00 ➝ $85.007/7/2026PTCTPTC Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.006/18/2026SRRKScholar Rock Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.005/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/27/2026PTCTPTC Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$76.00 ➝ $85.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/11/2026PTCTPTC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.00(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$10.27B0.17$7.11 per share0.67$1.02 per share4.67LNTHLantheus$1.55B4.31$6.20 per share16.50$16.43 per share6.23PTCTPTC Therapeutics$1.73B3.74$8.42 per share9.27($2.56) per share-30.49SRRKScholar RockN/AN/AN/AN/A$2.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos$157M-$3.24N/A1.31N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)LNTHLantheus$233.56M$4.1524.6719.03N/A18.05%29.32%15.00%8/5/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A37.003.74-22.58%-362.45%-6.76%8/6/2026 (Estimated)SRRKScholar Rock-$377.94M-$3.59N/AN/AN/AN/A-163.52%-96.67%8/5/2026 (Estimated)Latest BHC, PTCT, LNTH, and SRRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026PTCTPTC Therapeutics$0.3132N/AN/AN/A$294.00 millionN/A8/5/2026Q2 2026LNTHLantheus$1.33N/AN/AN/A$363.02 millionN/A8/5/2026Q2 2026SRRKScholar Rock-$0.84N/AN/AN/A$3.33 millionN/A7/29/2026Q2 2026BHCBausch Health Cos$0.96N/AN/AN/A$2.56 billionN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/7/2026Q1 2026SRRKScholar Rock-$0.82-$0.83-$0.01-$0.83$5.00 millionN/A4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos54.681.320.97LNTHLantheus0.472.832.64PTCTPTC TherapeuticsN/A2.442.36SRRKScholar Rock0.718.648.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%LNTHLantheus99.06%PTCTPTC TherapeuticsN/ASRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos20.67%LNTHLantheus1.70%PTCTPTC Therapeutics5.50%SRRKScholar Rock10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,300374.03 million296.72 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableSRRKScholar Rock140119.83 million107.49 millionOptionableBHC, PTCT, LNTH, and SRRK HeadlinesRecent News About These CompaniesScholar Rock Holding Corporation $SRRK Holdings Raised by Candriam S.C.A.July 13 at 3:51 AM | marketbeat.comSG Americas Securities LLC Cuts Stake in Scholar Rock Holding Corporation $SRRKJuly 9, 2026 | marketbeat.comKristina Burow Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) StockJuly 8, 2026 | americanbankingnews.comJeffrey Flier Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) StockJuly 8, 2026 | americanbankingnews.comJoshua Reed Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) StockJuly 8, 2026 | americanbankingnews.comKatie Peng Sells 5,446 Shares of Scholar Rock (NASDAQ:SRRK) StockJuly 8, 2026 | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Director Michael Gilman Sells 2,544 Shares of StockJuly 7, 2026 | americanbankingnews.comMichael Gilman Sells 2,544 Shares of Scholar Rock (NASDAQ:SRRK) StockJuly 7, 2026 | insidertrades.comPictet Asset Management Holding SA Cuts Stake in Scholar Rock Holding Corporation $SRRKJuly 1, 2026 | marketbeat.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from AnalystsJuly 1, 2026 | marketbeat.comScholar Rock: New Treatment Boost For SMA Patients -- With September PDUFAJune 25, 2026 | seekingalpha.comScholar Rock (NASDAQ:SRRK) Reaches New 52-Week High - What's Next?June 24, 2026 | marketbeat.comScholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHDJune 22, 2026 | finance.yahoo.comCasdin Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRKJune 18, 2026 | marketbeat.comArmistice Capital LLC Takes Position in Scholar Rock Holding Corporation $SRRKJune 18, 2026 | marketbeat.comGranahan Investment Management LLC Raises Stock Position in Scholar Rock Holding Corporation $SRRKJune 17, 2026 | marketbeat.comPolar Capital Holdings Plc Buys 527,929 Shares of Scholar Rock Holding Corporation $SRRKJune 17, 2026 | marketbeat.comWhy Scholar Rock’s Workforce Expansion Is Drawing Attention Across BiotechnologyJune 15, 2026 | kalkinemedia.comKScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 12, 2026 | businesswire.comScholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comScholar Rock Holding Corp.May 26, 2026 | edition.cnn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHC, PTCT, LNTH, and SRRK Company DescriptionsBausch Health Cos NYSE:BHC$4.76 -0.09 (-1.75%) Closing price 07/14/2026 03:59 PM EasternExtended Trading$4.86 +0.10 (+2.08%) As of 07/14/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Lantheus NASDAQ:LNTH$102.37 -3.02 (-2.87%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$101.12 -1.25 (-1.22%) As of 06:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.PTC Therapeutics NASDAQ:PTCT$78.06 -3.27 (-4.02%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$78.00 -0.06 (-0.08%) As of 06:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Scholar Rock NASDAQ:SRRK$53.78 -0.92 (-1.68%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$54.42 +0.64 (+1.20%) As of 05:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
